Enanta Pharmaceuticals (ENTA) Shareholder's Equity Growth (3y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.36% |
| Dec 31, 2025 | -25.06% |
| Sep 30, 2025 | -41.38% |
| Jun 30, 2025 | -38.33% |
| Mar 31, 2025 | -36.11% |
| Dec 31, 2024 | -33.74% |
| Sep 30, 2024 | -31.42% |
| Jun 30, 2024 | -29.10% |
| Mar 31, 2024 | -27.51% |
| Dec 31, 2023 | -24.84% |
| Sep 30, 2023 | -21.94% |
| Jun 30, 2023 | -20.90% |
| Mar 31, 2023 | -17.86% |
| Dec 31, 2022 | -14.56% |
| Sep 30, 2022 | -11.43% |
| Jun 30, 2022 | -8.97% |
| Mar 31, 2022 | -6.32% |
| Dec 31, 2021 | -3.43% |
| Sep 30, 2021 | 0.48% |
| Jun 30, 2021 | 5.01% |
| Mar 31, 2021 | 9.36% |
| Dec 31, 2020 | 12.48% |
| Sep 30, 2020 | 14.73% |
| Jun 30, 2020 | 22.59% |
| Mar 31, 2020 | 22.25% |
| Dec 31, 2019 | 21.61% |
| Sep 30, 2019 | 19.66% |
| Jun 30, 2019 | 18.54% |
| Mar 31, 2019 | 17.86% |
| Dec 31, 2018 | 17.33% |
| Sep 30, 2018 | 18.57% |
| Jun 30, 2018 | 16.49% |
| Mar 31, 2018 | 14.14% |
| Dec 31, 2017 | 17.91% |
| Sep 30, 2017 | 26.61% |
| Jun 30, 2017 | 19.48% |
| Mar 31, 2017 | 37.78% |
| Dec 31, 2016 | 36.44% |
| Sep 30, 2016 | 34.69% |
| Jun 30, 2016 | 32.97% |
| Mar 31, 2016 | 31.05% |
| Sep 30, 2015 | 59.36% |